Vivos Inc. is a radiation oncology medical device company engaged in the development of its yttrium-90 (“Y-90”) based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.
Company profile
Ticker
RDGL
Exchange
Website
CEO
Michael K. Korenko
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADVANCED MEDICAL ISOTOPE Corp
SEC CIK
Corporate docs
IRS number
800138937
RDGL stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
22 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Unregistered Sales of Equity Securities
27 Dec 23
253G2
Offering circular supplement
21 Dec 23
QUALIF
Notice of qualification
7 Dec 23
CORRESP
Correspondence with SEC
5 Dec 23
1-A POS
Offering $4.00 mm in Equity
27 Nov 23
CORRESP
Correspondence with SEC
27 Nov 23
UPLOAD
Letter from SEC
8 Nov 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.54 mm | 1.54 mm | 1.54 mm | 1.54 mm | 1.54 mm | 1.54 mm |
Cash burn (monthly) | 70.64 k | 37.57 k | 229.21 k | 213.00 k | 73.97 k | (no burn) |
Cash used (since last report) | 479.63 k | 255.11 k | 1.56 mm | 1.45 mm | 502.26 k | n/a |
Cash remaining | 1.06 mm | 1.28 mm | -19.42 k | 90.64 k | 1.03 mm | n/a |
Runway (months of cash) | 15.0 | 34.1 | -0.1 | 0.4 | 14.0 | n/a |
Institutional ownership, Q2 2022
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 9.00 k |
Total shares | 126.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Captrust Financial Advisors | 126.00 k | $9.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Nov 23 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.0517 | 100,000 | 5.17 k | 10,085,090 |
18 Oct 23 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.0536 | 100,000 | 5.36 k | 9,985,090 |
24 Mar 23 | Michael H Pollack | Common Stock | Sell | Dispose S | No | No | 0.0624 | 16,000 | 998.40 | 0 |
15 Dec 22 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.0466 | 100,000 | 4.66 k | 9,885,090 |
17 Nov 22 | Korenko Michael K | Common Stock | Buy | Acquire P | No | No | 0.0517 | 200,000 | 10.34 k | 9,785,090 |